Navigation Links
New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Date:10/3/2007

Lowest Dose of Estradiol Shown to Be Safe and Effective for Menopausal

Women

WEST PALM BEACH, Fla., Oct. 3 /PRNewswire/ -- A study presented today at the 2007 Annual Meeting of the North American Menopause Society (NAMS) revealed that Divigel(R) (estradiol gel) 0.1% significantly reduced the frequency and severity of moderate to severe hot flashes associated with menopause. Additional data presented at the meeting found that Divigel(R) is a safe and well-tolerated therapy offering the lowest approved dose of estradiol available for the treatment of hot flashes, the most common symptom of menopause.

"These data demonstrate that Divigel(R) is a safe and highly effective low dose therapy that quickly manages the uncomfortable side effects of menopause," said Dr. Ronald Ackerman, FACOG, CEO and principal investigator, Comprehensive Clinical Trials. "Women that have been reluctant to take older hormone therapies with higher doses of estrogen now have the choice of taking Divigel(R), the lowest dose of estradiol available."

Guidelines from the North American Menopause Society (NAMS) indicate that estrogen hormone therapy should be used at the lowest effective dose for the shortest amount of time.

"Divigel(R) is applied to the skin where it absorbs directly into the bloodstream without having to pass through the liver. This provides treatment continuity allowing women to use less estrogen than is needed in a pill because of the way the therapy is delivered," said Dr. Ackerman. "Transdermal therapies have been used in Europe for years, and they are becoming increasingly common in the United States. The availability of this lowest dose estrogen gel combined with its convenience makes Divigel(R) a valuable option for physicians and patients."

This 12-week study evaluated 488 postmenopausal women presenting with moderate to severe vasomotor symptoms. The study compared placebo to Divigel(R) at doses of 1
'/>"/>

SOURCE Comprehensive Clinical Trials
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
2. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
3. Waismann Method Survey Reveals Dependency Risk for People Using Suboxone
4. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
5. Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers
6. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
7. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
8. First-of-its-Kind National Report Reveals Estimated High Prevalence and Heavy Cost of Type 2 Diabetes Complications in America
9. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor
10. Survey Reveals Significant Public Lack of Diabetes Awareness
11. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... pirfenidone may provide meaningful clinical benefit in IPF patients ... reported -- Conference Call and Webcast at 9 p.m. ... InterMune, Inc. (Nasdaq: ITMN ) reported ... evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) ...
... 19 New data demonstrate that maintenance therapy with ... time to relapse compared to placebo in patients with ... this week at a major medical meeting. Bipolar ... in a person,s mood, energy and ability to function. ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:7/30/2014)... (PRWEB) July 30, 2014 Conducting ... Advanced Critical Thinking Skills and Innovative Techniques to ... Immel Resources and FDAnews**, Sept. 17-18, 2014 – ... been the #1 reason for 483 observations since ... clear: Developing a successful CAPA program has never ...
(Date:7/30/2014)... Good Neighbor Community Services announced ... episode of Innovations with Ed Begley Jr, airing ... show times TBA. , In this segment, viewers ... vision to redefine the traditional approach to serving ... Through passion, innovation, determination, excellence, and collaboration, Good ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 SF ... accessories at the lowest prices on the internet with ... Cables in two lengths and two colors. These lightning ... standards. , The high quality SF Cable ... connector with digital signal delivering faster charging and syncing. ...
(Date:7/30/2014)... July 30, 2014 Hamilton Facial ... of its new Carmel office on July 30th. After ... finally be moving to the state-of-the-art suite, located only ... innovative space will allow for one-on-one patient comfort, shorter ... experience. , Dr. Hamilton’s new office-suite will continue ...
(Date:7/30/2014)... ... ... ... , ... , For the study, published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by ...
Breaking Medicine News(10 mins):Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... OSLO, June 24 DiaGenic ASA (OSL: ... with Merz Pharmaceuticals,GmbH, an innovative developer of drugs for ... to biomarkers for Mild Cognitive,Impairment (MCI), increasingly considered a ... be used to identify patients with MCI,prone to converting ...
... ... most individuals know the importance of applying sunscreen regularly, but in a recent literature study ... be even more at risk for developing the deadly disease. , ... Rosemont, IL (Vocus) June 24, 2009 -- With ...
... ... prevention for at-risk horses. , ... Shenandoah, IA (PRWEB) June 24, 2009 -- Equine obesity is on the rise in the ... at a higher risk for laminitis: a debilitating condition responsible for thousands of deaths each ...
... ... sample and learn about their new products at the ASMBS conference. The Company located in ... ... Advantage, a Division of Catalina Lifesciences, could barely keep up with demand to sample and ...
... Cytox Limited, a UK-based neuroscience company that provides ... disease (AD) clinical trials, has announced completion of a ... million). , , Proceeds will be used ... AD and mild cognitive impairment (MCI). Cytox,s biomarkers help ...
... at greater risk of heart-rhythm abnormality: study , TUESDAY, ... severe sleep-related breathing problems are at increased risk for ... study included 2,911 men who underwent sleep testing between ... paused or shallow breathing during sleep were more likely ...
Cached Medicine News:Health News:DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals 2Health News:DiaGenic to Provide MCI Biomarkers for Merz Pharmaceuticals 3Health News:Study Finds Skin Cancer Rates Higher Among Athletes 2Health News:Equine Obesity is Associated with Significant Health Issues, Including Insulin Resistance and Laminitis 2Health News:Interest in the Bariatric Advantage Chewy Bites and Other New Products is at an All-Time High at the ASMBS Conference 2Health News:Cytox Raises Pre-Series A Financing From Management and Existing UK Investors, Welcomes First US Investors 2Health News:Cytox Raises Pre-Series A Financing From Management and Existing UK Investors, Welcomes First US Investors 3Health News:Cytox Raises Pre-Series A Financing From Management and Existing UK Investors, Welcomes First US Investors 4Health News:Sleep Disorders Linked to Arrhythmias 2
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
Medicine Products: